Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany; Member of the German Center for Lung Research (DZL), Munich, Germany.
Center for Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany.
Trends Cancer. 2022 Aug;8(8):670-682. doi: 10.1016/j.trecan.2022.04.001. Epub 2022 Apr 29.
Immune checkpoint inhibition and chimeric antigen receptor (CAR) T cell therapy have demonstrated stunning clinical efficacy in many cancer types. However, most patients do not respond to immunotherapies or relapse after an initial response, stressing the need for improved strategies. Chemokines, as mediators of immune cell trafficking, play an important role in the composition of the tumor microenvironment and exert both pro- and antitumorigenic functions. Here, chemokines may represent valuable prognostic biomarkers of response to immunotherapy and a strategy to improve immunotherapies. In this review, the pleiotropic functions of chemokines in the tumor microenvironment (TME) and strategies of utilizing chemokines or chemokine antagonism in immunotherapy are discussed. The review highlights preclinical and clinical studies that apply or target chemokines in monotherapy or in combination therapies.
免疫检查点抑制和嵌合抗原受体 (CAR) T 细胞疗法在许多癌症类型中显示出了惊人的临床疗效。然而，大多数患者对免疫疗法没有反应或在初始反应后复发，这强调了需要改进策略。趋化因子作为免疫细胞迁移的介质，在肿瘤微环境的组成中发挥着重要作用，并具有促进和抗肿瘤生成的功能。在这里，趋化因子可能代表了对免疫治疗反应的有价值的预后生物标志物，也是一种改善免疫治疗的策略。在这篇综述中，讨论了趋化因子在肿瘤微环境 (TME) 中的多效功能，以及利用趋化因子或趋化因子拮抗作用进行免疫治疗的策略。该综述强调了应用或靶向趋化因子的临床前和临床研究，无论是单独治疗还是联合治疗。
